UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): December 16, 2008
GERON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-20859 75-2287752
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
230 CONSTITUTION DRIVE
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices, including zip code)
(650) 473-7700
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Compensatory Arrangements of Certain Officers
On December 16, 2008, the Compensation Committee of the Board of Directors
of Geron Corporation (the "Company") approved (a) annual base salaries for 2009,
which are the same as the 2008 annual base salaries and (b) cash performance
bonuses for 2008 for the following principal executive officer, principal
financial officer and named executive officers of the Company:
--------------------------------------------------------------------------------------------------
2009
Salary 2009 2008
Name and Position Increase Base Salary Cash Bonus
--------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------
Thomas B. Okarma, Ph.D., M.D. $ -- $ 535,000 $ 280,900
President and CEO
--------------------------------------------------------------------------------------------------
David L. Greenwood $ -- $ 415,000 $ 163,400
Executive Vice President and CFO
--------------------------------------------------------------------------------------------------
Fabio M. Benedetti, M.D. $ -- $ 350,000 $ 102,300
Senior Vice President, Chief Medical
Officer, Oncology
--------------------------------------------------------------------------------------------------
David J. Earp, J.D., Ph.D. $ -- $ 325,000 $ 113,800
Senior Vice President, Bus. Dev. and
Chief Patent Counsel
--------------------------------------------------------------------------------------------------
Calvin B. Harley, Ph.D. $ -- $ 315,000 $ 96,500
Chief Scientific Officer
--------------------------------------------------------------------------------------------------
Melissa Kelly Behrs $ -- $ 320,000 $ 112,000
Senior Vice President, Therapeutic
Development, Oncology
--------------------------------------------------------------------------------------------------
Jane S. Lebkowski, Ph.D. $ -- $ 335,000 $ 117,300
Senior Vice President, Regenerative
Medicine
--------------------------------------------------------------------------------------------------
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GERON CORPORATION
Date: December 19, 2008 By: /s/ David L. Greenwood
--------------------------------------------
Name: David L. Greenwood
Title: Executive Vice President,
Chief Financial Officer